Five years of nationwide use of whole genome sequencing in ongoing pregnancies: Diagnostic yield, timing, and implementation
In brief
Prenatal genome sequencing diagnoses 16% of pregnancies after normal chromosome testing
In this nationwide study of 207 ongoing pregnancies, prenatal whole genome sequencing found a likely or confirmed cause in 33 cases, with results taking a median of 11 working days. The diagnostic yield was highest for hydrops and multiple anomalies, but the study did not assess how results affected parental decisions or pregnancy outcomes.
- Journal
- Acta obstetricia et gynecologica Scandinavica (Q1)
- Published
- 11 November 2026
- Study design
- Cohort / observational study
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Ida Vogel, Lotte Andreasen, Pernille Mathiesen Tørring, Marie Skov Hvidbjerg, Martin Larsen, Ida Charlotte Bay Lund, et al.
- PMID
- 43012340
- DOI
- 10.1111/aogs.70384
Why clinicians should know about it
- Picked for Genetics (clinical) (top studies of the week, 15 November 2026): Nationwide prenatal genome sequencing yield and implementation
Abstract
INTRODUCTION: We describe timing, diagnostic yield, secondary findings of prenatal whole genome sequencing (pWGS) in ongoing pregnancies during the first 5 years of implementation within a publicly funded healthcare system. Moreover, we discuss our collective clinical experiences implementing pWGS in prenatal care. MATERIAL AND METHODS: We conducted a historical cohort study, including all singleton pregnancies undergoing pWGS after a normal chromosomal microarray between 2019 and 2023. Data on sample type, gestational age at test ordering, turnaround time, diagnostic yield, and secondary findings were extracted from all four Danish clinical genetics laboratories. RESULTS: A total of 207 cases were analyzed, including 85 chorionic villus samples and 122 amniotic fluid samples; trio sequencing was performed in 204/207 (98.6%). Median gestational age at ordering was 20 weeks (IQR 17-21). Median turnaround time for ongoing pregnancies was 11 working days (IQR 8-17). Pathogenic or likely pathogenic variants explaining the phenotype were identified in 33/207 pregnancies (15.9%, 95% CI 11.6-21.5). Yield was highest in hydrops (25.0%, 95% CI 12.0-44.9) and multiple anomalies (24.3%, 95% CI 13.4-40.1), and lowest in isolated increased nuchal translucency (7.1%, 95% CI 2.0-22.6). Secondary findings were reported in 18/207 cases (8.7%, 95% CI 5.6-13.3). CONCLUSIONS: pWGS was delivered within clinically relevant turnaround times. Applied after normal chromosomal microarray, the yield represents incremental diagnostic value in a chromosomal microarray-negative population. In clinical practice, both normal and abnormal pWGS results form a central component of counseling in ongoing pregnancies with unresolved fetal risk. However, the impact of such results on parental decision-making or pregnancy outcomes was not assessed in this study.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.